# Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-301)

> **NCT03836287** · PHASE3 · COMPLETED · sponsor: **Botanix Pharmaceuticals** · enrollment: 350 (actual)

## Conditions studied

- Axillary Hyperhidrosis

## Interventions

- **DRUG:** Sofpironium Bromide Gel, 15%
- **DRUG:** Vehicle

## Key facts

- **NCT ID:** NCT03836287
- **Lead sponsor:** Botanix Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-09
- **Primary completion:** 2021-06-25
- **Final completion:** 2021-06-25
- **Target enrollment:** 350 (ACTUAL)
- **Last updated:** 2024-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03836287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03836287, "Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-301)". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT03836287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*